Linagliptin: all 129 studies that test it

Page 2 of 2. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female SubjectsCompletedNCT02183493Phase 1
• Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male SubjectsCompletedNCT02183467Phase 1
• Bioavailability of BI 1356 and Glyburide in Healthy Male and Female VolunteersCompletedNCT02183428Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 DiabetesCompletedNCT02183415Phase 1
• Pharmacokinetics, Safety and Tolerability of Digoxin With or Without Co-administration of BI 1356 in Healthy VolunteersCompletedNCT02183402Phase 1
• Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male VolunteersCompletedNCT02183389Phase 1
• Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy SubjectsCompletedNCT02183376Phase 1
• Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male VolunteersCompletedNCT02183363Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 DiabetesCompletedNCT02183350Phase 1
• Bioavailability of BI 1356 With and Without Co-administration of Pioglitazone and the Bioavailability of Pioglitazone With and Without Coadministration of BI 1356 in Healthy Male and Female VolunteersCompletedNCT02183337Phase 1
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male VolunteersCompletedNCT02183311Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male VolunteersCompletedNCT02183298Phase 1
• Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BSCompletedNCT02180503Phase 1
• Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal SubjectsCompletedNCT02175394Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male SubjectsCompletedNCT02173665Phase 1
• Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female VolunteersCompletedNCT02173652Phase 1
• Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female SubjectsCompletedNCT02173639Phase 1
• Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male VolunteersCompletedNCT02172222Phase 1
• Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 DiabetesCompletedNCT02106104Phase 4
• Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes MellitusStatus unknownNCT02097342Phase 4
• Safety Evaluation of Adverse Reactions in DiabetesCompletedNCT02092597Phase 4
• Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes MellitusTerminatedNCT02077309Phase 3
• Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early DiabetesCompletedNCT02015299Phase 3
• Linagliptin in Schizophrenia PatientsTerminatedNCT01943019Phase 1
• Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal ImpairmentCompletedNCT01903070Phase 4
• Diastolic Dysfunction in Patients With Type 2 Diabetes MellitusTerminatedNCT01888796Phase 3
• Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.CompletedNCT01835678Phase 3
• Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 DiabetesCompletedNCT01617824Phase 4
• Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes MellitusStatus unknownNCT01547104Phase 4

← Linagliptin overview